[Biostar Pharmaceuticals, Reports First Quarter 2011 Results; Revenuesrease 24% to $15.3 Million withjusted EPS of $0.11 XIANYANG, China, May 16, 2011 -- Biostar Pharmaceuticals, (Nasdaq: BSPM) ("Biostar" or "thempany"), Xianyang-based manufacturer of a leading over-the-counter Hepatitis B medicine, Xin Aoxing Oleanolic Acidpsules ("Xin Aoxingpsules"), and a variety of pharmaceutical products, today announced financial results for]
[Biostar Pharmaceuticals, Reports First Quarter 2011 Results; Revenuesrease 24% to $15.3 Million withjusted EPS of $0.11 XIANYANG, China, May 16, 2011 -- Biostar Pharmaceuticals, (Nasdaq: BSPM) ("Biostar" or "thempany"), Xianyang-based manufacturer of a leading over-the-counter Hepatitis B medicine, Xin Aoxing Oleanolic Acidpsules ("Xin Aoxingpsules"), and a variety of pharmaceutical products, today announced financial results for]
[FORM 10-Q (Mark One) x March 31, 2011 For the quarterly period ended: Or For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, Maryland 20-8747899 (State or other jurisdiction oforporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province Peoples Republic of China] [EMPLOYMENTREEMENT THIS EMPLOYMENTREEMENT W I T N E S S E T H: WHEREAS WHEREAS NOW, THEREFORE 1. Employment of Chief Financial Officer of thempany . 2. Term 1 4.mpensation . a. (i)Executive shall be paid a base pay of USD 10,000 per month during the term, payable on the lasty of each month.] [CERTIFICATION I, Ronghua Wang, certify that: 1. I have reviewed this quarterly 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with] [CERTIFICATION I, Zack Pan, certify that: 1. I have reviewed this quarterly 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with] [CERTIFICATION (1) (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany at thetes and for the periods indicated. ex32-1.htm 5 EX-32.1] [CERTIFICATION (1) (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany at thetes and for the periods indicated. ex32-2.htm 6 EX-32.2]
[FORM 10-Q (Mark One) x March 31, 2011 For the quarterly period ended: Or For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, Maryland 20-8747899 (State or other jurisdiction oforporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province Peoples Republic of China] [EMPLOYMENTREEMENT THIS EMPLOYMENTREEMENT W I T N E S S E T H: WHEREAS WHEREAS NOW, THEREFORE 1. Employment of Chief Financial Officer of thempany . 2. Term 1 4.mpensation . a. (i)Executive shall be paid a base pay of USD 10,000 per month during the term, payable on the lasty of each month.] [CERTIFICATION I, Ronghua Wang, certify that: 1. I have reviewed this quarterly 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with] [CERTIFICATION I, Zack Pan, certify that: 1. I have reviewed this quarterly 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with] [CERTIFICATION (1) (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany at thetes and for the periods indicated. ex32-1.htm 5 EX-32.1] [CERTIFICATION (1) (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany at thetes and for the periods indicated. ex32-2.htm 6 EX-32.2]
[SKYSTAR BIO-PHARMACEUTICALMPANY N/A Former name if applicable: 9595 Wilshire Blvd., Suite 900 Beverly Hills,lifornia 90212 City, state and zipde PART II -- RULES 12b-25(b) AND (c) (a) The reasons described in reasonable detail in Part III of this formuld not be eliminated without unreasonable effort or expense;]
[SKYSTAR BIO-PHARMACEUTICALMPANY N/A Former name if applicable: 9595 Wilshire Blvd., Suite 900 Beverly Hills,lifornia 90212 City, state and zipde PART II -- RULES 12b-25(b) AND (c) (a) The reasons described in reasonable detail in Part III of this formuld not be eliminated without unreasonable effort or expense;]
[Tianyin Pharmaceutical Co., Inc. NYSE Amex: TPI rd 23 May 12, 2011 Division of Corporate Finance 100 F. Street, N.E. Attn: Frank Wyman Re: Tianyin Pharmaceutical Co., Inc. Form 10-K for the Fiscal Year Ended June 30, 2009 Form 10-Q for Quarterly Period Ended December 31, 2009 File No. 001-34189 Dear Mr. Wyman: In response to your letter dated February]
[Tianyin Pharmaceutical Co., Inc. NYSE Amex: TPI rd 23 May 12, 2011 Division of Corporate Finance 100 F. Street, N.E. Attn: Frank Wyman Re: Tianyin Pharmaceutical Co., Inc. Form 10-K for the Fiscal Year Ended June 30, 2009 Form 10-Q for Quarterly Period Ended December 31, 2009 File No. 001-34189 Dear Mr. Wyman: In response to your letter dated February]
[Form 6-K TABLE OF CONTENTS Page 3 4 PRESS RELEASE DATED MAY 10, 2011]
[Form 6-K TABLE OF CONTENTS Page 3 4 PRESS RELEASE DATED MAY 10, 2011]
